CTI is a precision-formulated Growth Hormone axis support blend combining CJC 3mg, Tesamorelin 6mg, and Ipamorelin 3mg in a 12mg / 2mL pen-system cartridge. This balanced peptide combination is designed to support natural pulsatile growth hormone release, improve recovery, assist with body recomposition, and help preserve lean tissue during dieting or performance-focused phases.

By combining a GHRH-based approach with a selective GHRP, CTI is positioned for users looking for broader GH-axis support rather than relying on a single pathway alone. It is particularly well suited to recovery support, sleep quality, metabolic optimisation, and abdominal fat-loss strategies where maintaining muscle tissue matters.

How It Works and Research Findings

CTI works by supporting the body’s own growth hormone signalling through complementary mechanisms.

CJC

CJC acts as a GHRH analogue, supporting the amplitude of natural GH pulses. It is commonly used where recovery, sleep quality, tissue repair, and anabolic support are desired.

Tesamorelin

Tesamorelin is a clinically recognised GHRH analogue best known for its association with visceral fat reduction and a more pronounced IGF-1 response. Within this blend, it strengthens the metabolic and body-composition side of the formula.

Ipamorelin

Ipamorelin is a selective GHRP that promotes GH release while generally being viewed as a cleaner option than older GHRPs, with less tendency toward unwanted cortisol or prolactin spillover. It also complements the GHRH components by helping support more complete GH pulse signalling.

Why the Combination Matters

Used together, these three compounds are intended to support:

• stronger GH pulse support
• improved recovery and training readiness
• better sleep-related anabolic signalling
• support for lipolysis and abdominal fat reduction
• preservation of lean tissue during calorie restriction or recomposition phases

This makes CTI a useful option for users focused on recovery, visceral fat targeting, lean mass retention, and general GH-axis optimisation.

Dosage Protocol Using the Pen System

Product Strength

Total strength: 12mg / 2mL
Pen system: 200 clicks per 2mL cartridge

Blend Breakdown

• CJC: 3mg
• Tesamorelin: 6mg
• Ipamorelin: 3mg

Concentration

6mg/mL

Per Click Dosing

Each click delivers 0.06mg (60mcg) total blend

• CJC: 15mcg
• Tesamorelin: 30mcg
• Ipamorelin: 15mcg

Click-to-Dose Scale

Dosing Strategies

Entry / Recovery Support

10 clicks once daily

Best used pre-bed, where sleep-related GH pulses are the main goal, or morning fasted depending on routine and preference.

Recomposition / Visceral Fat Support

10 clicks in the morning + 10 clicks pre-bed
Total: 20 clicks daily

This approach is more suitable where fat-loss support and metabolic effect are the main goals.

Advanced GH-Axis Optimisation

15–20 clicks daily, typically split AM and PM.

For longer or higher-dose runs, periodic IGF-1 review is sensible.

Cycle Structure

• Standard use: 8–12 weeks on, then 4 weeks off
• Recomposition focus: 12 weeks on, then reassess body composition and response
• Lower-dose longer-term use: 10 clicks daily, with a 4-week break every 16–20 weeks

Expected Outcomes

Results will vary depending on diet, sleep, training, and total metabolic load, but typical progression may include:

Weeks 1–2

• improved sleep depth
• better recovery
• improved training readiness

Weeks 3–6

• changes in abdominal softness
• improved fullness and recovery between sessions
• more noticeable day-to-day resilience

Weeks 6–12

• improved body recomposition
• reduction in visceral-fat appearance
• leaner waistline and better metabolic efficiency

CTI is generally best positioned as a supportive recomposition and recovery tool, rather than a rapid standalone fat-loss product.

Cautions and Warnings

Potential side effects may include:

• mild water retention
• hand tingling or numbness
• increased hunger
• elevated IGF-1 on extended or higher-dose use

Avoid use in cases of:

• active malignancy
• pregnancy
• uncontrolled diabetes

Where longer cycles or higher-dose strategies are used, periodic IGF-1 and general metabolic monitoring should be considered.

Related Products

• CJC + Ipamorelin
• Tesamorelin
• Retatrutide
• Tirzepatide
• MOTS-C